retatrutide type 2 diabetes trial Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Phase 2: Type 2

All treatments require evaluation and guidance from a licensed healthcare provider

Headline Trial Results The SLIMMER Phase 3 study enrolled 664 adults with overweight or obesity

1 Introduction Incretin peptides are secreted from the intestine after nutrient ingestion and enhance glucose-stimulated insulin secretion ( 2 Weight loss pharmacotherapies 2.1 GLP-1R and GIPR agonism reduce body weight in patients with obesity Early GLP-1R agonists were approved to treat T2D ( The mechanism underlying the impressive weight loss potential of GLP-1R agonists is primarily, if not exclusively, mediated by a reduction in energy intake

Who should consider the GLP-1 pill

Because PREDIMED collected detailed diet data year after year, the authors could estimate how much lycopene each man was getting from his food, mainly from tomatoes and tomato-based dishes, and then watch who did and did not go on to develop prostate cancer over an average of 5.8 years

For example, chitosan, chitooligosaccharides, and chitosan-derivates have demonstrated anti-obesogenic effects through different mechanisms: inhibition of PPAR-, stimulation of glucokinase, reduction of leptin, adiponectin, and resistin levels, inhibition of adipogenesis, lipid metabolism modulation, and suppression of phosphoenolpyruvate carboxylase (Shagdarova et al., 2023)